Search bioRxivSearch

Biology subjects

Emmanuel Martinez-Ledesma

Publications and source records attributed to Emmanuel Martinez-Ledesma.

2 recordsLinked to original sources

Identification of outcome-related driver mutations in cancer using conditional co-occurrence distributions

The methods proposed for the detection of cancer driver mutations are based on the estimation of background mutation rate, impact on protein function, or network influence. Instead, we focus on those influencing patient survival. For this, an approximation of the log-rank test has been systematically applied even though it assumes a large and similar number of patients in both risk groups, which is violated in cancer genomics. Here, we propose VALORATE, a novel algorithm for the estimation of the null distribution for the log-rank test independently of the number of mutations. VALORATE is based on conditional distributions of the co-occurrences between events and mutations. The results using simulations, comparisons with other methods, TCGA and ICGC cancer datasets, and validations, suggests that VALORATE is accurate, fast, and can identify known and novel gene mutations. Our proposal and results may have important implications in cancer biology, in bioinformatics analyses, and ultimately in precision medicine.

Bioinformatics

Tumor evolution of glioma intrinsic gene expression subtype associates with immunological changes in the microenvironment

SummaryWe leveraged IDH wild type glioblastomas and derivative neurospheres to define tumor-intrinsic transcription phenotypes. Transcriptomic multiplicity correlated with increased intratumoral heterogeneity and tumor microenvironment presence. In silico cell sorting demonstrated that M2 macrophages/microglia are the most frequent type of immune cells in the glioma microenvironment, followed by CD4 T lymphocytes and neutrophils. Hypermutation associated with CD8+ T cell enrichment. Longitudinal transcriptome analysis of 124 pairs of primary and recurrent gliomas showed expression subtype is retained in 53% of cases with no proneural to mesenchymal transition being apparent. Inference of the tumor microenvironment through gene signatures revealed a decrease in invading monocytes but a subtype dependent increase in M2 macrophages/microglia cells after disease recurrence. All expression datasets are accessible through http://recur.bioinfo.cnio.es/.\n\nSignificanceIDH wild type glioblastoma expression phenotypes have been related to tumor characteristics including genomic abnormalities and treatment response. We explored the intratumoral transcriptomic landscape, including a definition of tumor-intrinsic gene expression subtypes and how they relate to the different cellular components of the tumor immune environment. Comparison of matching primary and recurrent gliomas provided insights into the treatment-induced phenotypic tumor evolution. Proneural to mesenchymal transitions have long been suspected but were not apparent, while intratumoral heterogeneity was a predictor of subtype transition upon recurrence. Characterizing the evolving glioblastoma transcriptome en tumor microenvironment aids in designing more effective immunotherapy trials. Our study provides a comprehensive transcriptional and cellular landscape of IDH wild type GBM during treatment modulated tumor evolution.\n\nHighlightsO_LINext generation GBM-intrinsic transcriptional subtypes: proneural, classical, mesenchymal\nC_LIO_LIM2 macrophages, CD4+ T-lymphocytes and neutrophils dominate glioblastoma microenvironment\nC_LIO_LISensitivity to radiotherapy may associate with M2 macrophage presence\nC_LIO_LICD8+ T cells are enriched in hypermutated GBMs at diagnosis and recurrence\nC_LI

Preprint